test

C80802: Phase III Randomized Study of Sorafenib Plus Doxorubicin versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)

Conditions

Liver

Trial Phase

Phase III

Trial Purpose and Description

Trial Purpose

Primary - Compare overall survival (OS) of patients treated with sorafenib and doxorubicin to that of those treated with sorafenib. Secondary - Compare time to progression (TTP) of patients treated with sorafenib and doxorubicin to that of those treated with sorafenib; compare progression-free-survival (PFS) of patients treated with sorafenib and doxorubicin to that of those treated with sorafenib; compare tumor response using RECIST criteria of patients treated with sorafenib and doxorubicin to that of those treated with sorafenib.


Participation Guidelines

Age:
Gender:

Eligibility Criteria

Sponsor:
CALGB
Dates:
05/07/2014
Last Updated:
Study HIC#:
1107008793